Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$41.12 USD
+0.14 (0.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $41.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
MIRM 41.12 +0.14(0.34%)
Will MIRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
Other News for MIRM
Franklin Biotechnology Discovery Fund Q2 2024 Commentary
Franklin Convertible Securities Fund Q2 2024 Commentary
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)